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In this issue of Cancer Cell, Fan and coworkers describe a novel inhibitor of PI3 kinase (PI3K) that potently interferes with the 
growth of glioma cells. They show that the efficacy of this inhibitor results from dual, synergistic activity against the p110α 
subunit of PI3K and against TOR. Although p110α and TOR belong to the same signaling pathway, they both must be inacti-
vated because of the need to silence the regulatory feedback loop that remains unaffected by monospecific inhibitors. The 
new PI3K inhibitor achieves the effects of combination therapy as a single agent by fortuitously hitting two critical targets.PI3K as a cancer target
The family of PI3 kinases (PI3Ks) has 
now joined protein kinases as a class of 
attractive and promising targets for small 
molecule inhibitors that have therapeutic 
potential in cancer. Of particular interest 
are the four isoforms of class 1 PI3K, 
p110α, -β, -γ, and -δ. They generate 
phosphatidylinositol-3,4,5-trisphosphate 
(PIP3), an important second messenger 
molecule that sets in motion complex 
growth-promoting signaling chains in the 
cell. Gain of function in PI3K-dependent 
signaling is common in cancer. It has 
three principal causes: amplification of 
the PIK3CA gene, which codes for the 
catalytic subunit p110α of class 1 PI3K; 
point mutations in that same gene; or loss 
of function in PTEN, the lipid phosphatase 
catalyzing the conversion of PIP3 into PIP2 
(Bader et al., 2005; Vivanco and Sawyers, 
2002). Increased PI3K activity can be a 
significant and even critical determinant 
of the oncogenic cellular phenotype, sug-
gesting that PI3K could be an important 
cancer target. When fused to a sequence 
that mediates membrane localization, 
p110α functions as a retroviral oncopro-
tein, inducing transformation in cell cul-
ture and tumors in the animal (Chang et 
al., 1997). Gain-of-function mutations in 
p110α that are derived from human can-
cer confer oncogenicity onto the protein 
in vitro and in vivo (Vogt et al., 2006). 
Inhibition of the downstream effector of 
PI3K, the protein kinase TOR, interferes 
with PI3K-induced oncogenic transfor-
mation in cell culture. In animal model 
systems, inhibition of TOR can impede 
the growth of tumors that show a gain of 
function in PI3K signaling (Bader et al., 
2006; Neshat et al., 2001; Podsypanina et 
al., 2001). These observations document 
dependence of oncogenic properties on 
PI3K signaling. Other reasons for the 
attractiveness of PI3K as a cancer target 
include the facts that PI3K is an enzyme 
and hence can readily be manipulated 
with small molecules, and that it shows 
gain of function in cancer, a condition 
that is easier to correct than loss of func-
tion. However, the identification of small cancer cell 9, May 2006 ©2006 ElsEviEr inmolecule inhibitors for PI3K has encoun-
tered some of the same problems that are 
known from inhibitors of protein kinases.
Lessons from inhibitors of protein 
kinases
Protein kinases are important cancer 
targets. Clinical experience with Gleevec 
in chronic myelogenous leukemia (CML) 
and Iressa and Tarceva in non-small cell 
lung cancer has shown that small mol-
ecule kinase inhibitors can be therapeuti-
cally highly effective (Druker, 2004). Yet 
these clinically successful compounds 
constitute an exception. The majority of 
Figure 1. compound Pi-103 inhibits Pi3K 
and TOr
This target combination is essential for the 
ability of Pi-103 to arrest the growth of glio-
ma cells and may reflect the need to inter-
fere with both the forward signal from Pi3K 
and the negative feedback from TOr for an 
effective shutdown of the signaling chain. 
as indicated by the question marks, there is 
still uncertainty about the precise upstream 
targets and their relative importance for the 
negative feedback loop. irs, insulin recep-
tor substrate; Pi3K, phosphoinositide 3 kinase; 
aKT, serine-threonine kinase akt; Tsc, tuber-
ous sclerosis complex; rHEB, ras homolog 
enriched in brain; TOr, target of rapamycin; 
s6K, s6 protein kinase.c. protein kinase inhibitors lack clinical util-
ity. One reason for this limited success 
lies in the mechanism by which most 
kinase inhibitors work: they compete with 
ATP by targeting the ATP binding site of 
the kinase. Since ATP pockets of differ-
ent kinases are structurally similar, these 
inhibitors typically not only affect the 
intended target molecule but also indis-
criminately inhibit the activities of sev-
eral other kinases as well (Fabian et al., 
2005). Such broad reactivity is generally 
perceived as an undesirable feature, as it 
can lead to side effects that disqualify the 
compound as a safe and effective drug. 
Yet there are situations where vice can 
turn into virtue and where lack of narrow 
target specificity has advantages. Hitting 
multiple kinases can expand clinical util-
ity to diseases for which the drug was not 
originally intended. Broad reactivity could 
also be an important factor determining 
drug efficacy. Gleevec is the now clas-
sic example of a protein kinase inhibitor 
with several targets (ABL, KIT, PDGFR) 
(Fabian et al., 2005). Initially developed to 
target BCR-ABL, the kinase driving CML, 
Gleevec has gained a second important 
application in the treatment of gastrointes-
tinal stromal tumors because of its addi-
tional activity against KIT. Even in CML, 
Gleevec may suppress other signaling 
pathways besides BCR-ABL.
Selective promiscuity
In this issue of Cancer Cell, Fan and 
coworkers provide an example from 
the young field of PI3K inhibitors for 
the unexpected benefits of broad target 
specificity (Fan et al., 2006). They gen-
erated ten structurally distinct inhibitors 
that show selectivity for one or more of 
the four class 1 PI3K isoforms and then 
determined which of these isoforms is 
critical for the growth of glioma cells in 
culture. p110α emerged as the relevant 
driving force, as only the inhibitors selec-
tive for this isoform effectively reduced 
the growth of glioma cells. Blockade of 
p110α alone, however, was not sufficient 
to achieve the maximum inhibitory effect. 
The compound with the most potent 
growth-arresting activity, PI-103, inhib-327
	 p r e v i e w sited not only p110α but also its down-
stream effector, the protein kinase TOR. 
Broad inhibitory action was essential for 
shutting down the growth of glioma cells. 
However, in order to be effective, the pro-
miscuity of the drug had to be targeted to 
PI3K and TOR. Then, and only then, did 
vice become a virtue, with PI-103 achiev-
ing the effects of combination therapy as 
a single agent (Figure 1).
Specificity of target combination
Given the complexity of cellular signaling 
and the ability of cells to compensate for 
loss of function, it comes as no surprise 
that more than one kinase needs to be 
inhibited to achieve a significant change 
in the cellular phenotype. The effects on 
multiple targets need to be complemen-
tary and then are synergistic. The action 
of the new PI3K inhibitor lends support to 
a model of PI3K signaling that includes as 
an essential feature a negative feedback 
loop originating from TOR and targeting 
an upstream component of the signal-
ing chain (Hay, 2005; Wullschleger et al., 
2006). An inhibitor directed to TOR alone 
weakens this negative feedback and 
results in activation of the PI3K signaling 
pathway. Only the dual PI3K-TOR inhibi-
tor can prevent this compensatory effect 
(Figure 1) (Fan et al., 2006). Among the 328 
In his classic film Rashomon, Akira 
Kurosawa told the story of a samurai’s 
death from four distinct points of view and 
presented his rain-soaked protagonists, 
and us, with the changing nature of truth. 
In this issue of Cancer Cell, Certo et al. 
(2006) provide a new perspective on how 
cells die and provide a possible resolution 
to a controversy that focuses on the heart 
of this process, at the gates of death. As 
in Rashomon, we can find four different 
and perhaps not completely incompatible 
At the gates of death
Apoptosis that proceeds via the mitocho
responsible for the release of cytochrom
step is controlled and mediated by protei
while the antiapoptotic Bcl-2 proteins, in
only proteins act to interfere with the fu
discuss an emerging view, proposed by
and apoptosis.compounds tested, the inhibitor PI-103 
is also the most effective in reducing Akt 
phosphorylation. A particularly gratifying 
quality of the dual PI3K-TOR inhibitor PI-
103 is its lack of toxicity. This fact allays 
fears that PI3K inhibitors may induce 
intolerable side effects on essential cel-
lular activities such as insulin signaling. 
With the identification of p110α and TOR 
as a critical target combination in glioma, 
the stage is set for rapid progress in the 
field of PI3K inhibitors.
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ized. Upon MOMP, holocytochrome c con-
tacts APAF-1, inducing the latter to recruit 
and activate caspase-9. Caspase-9 in turn 
cleaves and thereby activates executioner 
caspases, which then orchestrate apop-
tosis. Even without downstream caspase 
activation, however, MOMP appears to be 
sufficient to commit most cells to die, and 
death can proceed following MOMP in a 
caspase-independent manner. Therefore, 
MOMP is a critical decision point at which 
cell life and death is determined.
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